The ASEAN poultry vaccines market size was estimated at US$ 129.33 million in 2022 it is predicted to grow at a CAGR of 8.86% from 2023 to 2032 to reach around US$ 302.26 million by the end of 2032.
The ASEAN poultry vaccines market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global ASEAN poultry vaccines market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global ASEAN poultry vaccines market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.visionresearchreports.com/report/sample/39944
| Report Coverage | Details |
| Report Market Size in 2022 | USD 129.33 billion |
| Revenue Forecast by 2032 | USD 302.26 billion |
| Growth rate from 2023 to 2032 | CAGR of 8.86% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segmentation | Product, application, disease type |
| Companies Covered | Boehringer Ingelheim International GmbH;Ceva; HIPRA; Zoetis; Phibro Animal Health Corporation; Elanco; Merck & Co., Inc.; Medion Farma; Malaysian Vaccines & Pharmaceuticals Sdn Bhd.; Kemin Industries, Inc. |
This study covers an elaborate segmentation of the global ASEAN poultry vaccines market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global ASEAN poultry vaccines market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
Market Segmentation
- By Product Outlook
- Attenuated Live Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- DNA Vaccines
- Recombinant Vaccines
- By Application Outlook
- Broiler
- Layer
- Breeder
- By Disease Type Outlook
- Infectious Bronchitis
- Infectious Bursal Diseases
- Infectious Laryngotracheitis
- Egg Drop Syndrome
- Adenovirus
- Duck Viral Enteritis
- Inclusion Body Hepatitis
- Coccidiosis
- Avian Influenza
- Marek’s Disease
- Newcastle Disease
- Salmonella
- Avian Encephalomyelitis
- Fowl Cholera
- Others
- By Country Outlook
- Thailand
- Vietnam
- Cambodia
- Indonesia
- Laos
- Malaysia
- Philippines
- Myanmar
Research Methodology
The research methodology acquire by analysts for assemble the global ASEAN poultry vaccines market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global ASEAN poultry vaccines market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on ASEAN Poultry Vaccines Market
5.1. COVID-19 Landscape: ASEAN Poultry Vaccines Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. ASEAN Poultry Vaccines Market, By Product
8.1. ASEAN Poultry Vaccines Market, by Product, 2023-2032
8.1.1 Attenuated Live Vaccines
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Inactivated Vaccines
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Subunit Vaccines
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. DNA Vaccines
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Recombinant Vaccines
8.1.5.1. Market Revenue and Forecast (2019-2032)
Chapter 9. ASEAN Poultry Vaccines Market, By Application
9.1. ASEAN Poultry Vaccines Market, by Application, 2023-2032
9.1.1. Broiler
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Layer
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Breeder
9.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 10. ASEAN Poultry Vaccines Market, By Disease Type
10.1. ASEAN Poultry Vaccines Market, by Disease Type, 2023-2032
10.1.1. Infectious Bronchitis
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Infectious Bursal Diseases
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Infectious Laryngotracheitis
10.1.3.1. Market Revenue and Forecast (2019-2032)
10.1.4. Egg Drop Syndrome
10.1.4.1. Market Revenue and Forecast (2019-2032)
10.1.5. Adenovirus
10.1.5.1. Market Revenue and Forecast (2019-2032)
10.1.6. Duck Viral Enteritis
10.1.6.1. Market Revenue and Forecast (2019-2032)
10.1.7. Inclusion Body Hepatitis
10.1.7.1. Market Revenue and Forecast (2019-2032)
10.1.8. Coccidiosis
10.1.8.1. Market Revenue and Forecast (2019-2032)
10.1.9. Avian Influenza
10.1.9.1. Market Revenue and Forecast (2019-2032)
10.1.10. Marek’s Disease
10.1.10.1. Market Revenue and Forecast (2019-2032)
10.1.11. Newcastle Disease
10.1.11.1. Market Revenue and Forecast (2019-2032)
10.1.12. Salmonella
10.1.12.1. Market Revenue and Forecast (2019-2032)
10.1.13. Avian Encephalomyelitis
10.1.13.1. Market Revenue and Forecast (2019-2032)
10.1.14. Fowl Cholera
10.1.14.1. Market Revenue and Forecast (2019-2032)
10.1.15. Others
10.1.15.1. Market Revenue and Forecast (2019-2032)
Chapter 11. ASEAN Poultry Vaccines Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2032)
11.1.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2032)
11.2.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.6.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.7.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2032)
11.3.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.6.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.7.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.6.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.7.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.4.3. Market Revenue and Forecast, by Disease Type (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.5.3. Market Revenue and Forecast, by Disease Type (2019-2032)
Chapter 12. Company Profiles
12.1. Boehringer Ingelheim International GmbH
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Ceva
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. HIPRA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Zoetis
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Phibro Animal Health Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Elanco
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Medion Farma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Vision Research Reports
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168